Quick answer: the only published human trial of ipamorelin found more low potassium (12.5% vs 3.4%), insomnia (10.7% vs 5.2%) and high blood sugar at discharge (14.3% vs 8.6%) than placebo, in patients given it by IV after bowel surgery.[1][2] Two patients on ipamorelin died of surgical complications; FDA said it is unclear whether these were related.[1] Ipamorelin side effects from injection under the skin, the way it is usually sold, have never been studied.[1]
This guide covers the trial data, what FDA concluded, effects suggested by animal studies, product quality risks and who should be cautious. For background, see our ipamorelin profile and the growth hormone peptides hub.
Where the safety data come from
Human safety information on ipamorelin is thin:
- One healthy-volunteer study of single 15-minute IV infusions, which did not report adverse events.[3][1]
- One published phase 2 trial in 114 adults after bowel resection, given 0.03 mg per kg by IV twice daily for up to 7 days.[2]
- One larger trial of 320 patients that finished in 2014 but has never posted results.[9]
FDA reviewed all of this in 2024 and concluded there are no safety data for the subcutaneous (under the skin) route proposed for compounding.[1]
Side effects in the surgery trial
The trial’s authors described ipamorelin as well tolerated. Treatment-emergent adverse events of any kind occurred in 87.5% of ipamorelin patients and 94.8% of placebo patients, which is expected after major surgery.[2] FDA’s review pulled out the differences:[1]
| Side effect | Ipamorelin | Placebo |
|---|---|---|
| Low potassium (hypokalemia) | 12.5% | 3.4% |
| Insomnia | 10.7% | 5.2% |
| High blood sugar at discharge | 14.3% | 8.6% |
| Any serious adverse event | 17.9% | 15.5% |
| Readmitted within 30 days | 12.5% | 8.6% |
- Common in both groups: nausea, vomiting and abdominal bloating, slightly less often on ipamorelin.[1]
- Stopping treatment: three patients on ipamorelin stopped because of nausea, high blood pressure or low blood pressure; three on placebo also stopped.[1]
- Deaths: two patients on ipamorelin, both having surgery for colon cancer, developed leaks at the bowel join and later died of complications including sepsis and kidney failure. FDA said it is unclear whether the deaths were related to ipamorelin, but their occurrence, together with the higher rates of low potassium and high blood sugar, raised safety concerns.[1]
These were hospital patients recovering from major surgery, so the results may not reflect what happens in healthy people. They are still the only controlled human safety data that exist.
Blood sugar and other hormone-related effects
FDA noted that the nomination did not show ipamorelin avoids the problems seen with approved drugs that raise growth hormone, such as glucose intolerance and diabetes.[1] The higher rate of high blood sugar in the surgery trial fits that concern.
A 2026 endocrine review of growth hormone-axis peptides, including ipamorelin, listed the adverse effects clinicians see in people self-administering them: prolactin and cortisol rises, appetite changes, abnormal blood sugar, fluid retention, muscle and joint aches, and injection-site reactions.[8]
Is ipamorelin really “selective”?
Ipamorelin was promoted as the first selective growth hormone secretagogue. In pigs, it released growth hormone without raising ACTH or cortisol, even at doses more than 200 times higher than needed, while GHRP-2 and GHRP-6 did raise them. It also did not change prolactin, LH, FSH or TSH.[4]
That selectivity was shown in animals. The main human study measured growth hormone, not stress hormones or prolactin.[3] For how this compares with older peptides, see ipamorelin vs GHRP-6 and hexarelin vs ipamorelin.
Hunger, weight gain and other animal findings
- More fat, not less: in mice, twice-daily ipamorelin injections increased body weight by about 15% and raised body fat, even in mice unable to make growth hormone. In normal mice it also increased food intake.[5]
- Behavior and reproduction: FDA flagged that, as a ghrelin-receptor agonist, ipamorelin may have reinforcing properties that could contribute to addiction and may affect reproductive health and pregnancy, and that animal toxicity studies were too limited to judge.[1]
Reports from compounded products
FDA’s adverse event database held only two ipamorelin reports through September 30, 2023, both non-serious and both involving compounded or unregulated products:[1]
- A man using a nasal spray containing ipamorelin for 17 days reported headache and watery eyes, thought to be a product quality issue.
- A man injecting an ipamorelin and sermorelin mix for 2 months reported elbow joint pain that eased but did not fully resolve after stopping.
Few reports does not mean few problems: FDA notes that it does not receive all adverse event reports, especially for compounded products.[1]
Product quality and immune risks
FDA lists ipamorelin acetate as a substance that may present significant safety risks for outsourcing facilities. Its reasons:[6]
- Risk of immune reactions from clumped peptide (aggregation) or peptide-related impurities.
- Unnatural amino acids that make the peptide harder to characterize and test.
- Serious adverse events, including death, in the published IV trial.
In October 2024, FDA’s advisory committee voted 0 to 12, with one abstention, against allowing traditional pharmacies to compound it, citing a lack of safety and effectiveness data.[7] A 2026 sports medicine review added that rigorous human safety data are scarce for many unapproved peptides, including ipamorelin.[10]
For general guidance, see our overviews of peptide side effects and peptide injection-site reactions.
Who should be cautious
Given the limited data, talk carefully with a clinician before using ipamorelin if you:
- Have diabetes, prediabetes or a history of high blood sugar.
- Have low potassium or take medicines that can lower it.
- Are pregnant, trying to conceive or breastfeeding.
- Compete in tested sport; ipamorelin is on the World Anti-Doping Agency’s prohibited list.[1]
For what doses were studied, see our ipamorelin dosage guide. For a comparison with a GHRH-type peptide, see sermorelin vs ipamorelin.
Questions to ask a clinician
- What human safety data support using ipamorelin under the skin?
- Will you check my glucose, potassium and IGF-1?
- Which symptoms should make me stop and call you?
- Is there an FDA-approved alternative for my goal?
Report suspected side effects to your clinician and to FDA’s MedWatch program.
